Management and clinical outcomes of chronic liver disease with portal hypertension: a case study

Authors

  • G Venkata Nagaraju Department of Pharmacy Practice, Hindu College of Pharmacy, Amaravati Road, Guntur, A.P, India
  • MD.Ahmed Hussain Department of Pharmacy Practice, Hindu College of Pharmacy, Amaravati Road, Guntur, A.P, India

Abstract

Portal hypertension is a common complication of chronic liver diseases and is a significant contributor to many clinical consequences of cirrhosis. These complications often represent the leading causes of mortality and the need for liver transplantation in affected individuals. Chronic liver disease is a progressive condition characterized by persistent inflammation, fibrosis, and cirrhosis, which are frequently accompanied by portal hypertension. This study aims to evaluate the management strategies for chronic liver disease complicated by portal hypertension at Government General Hospital, Guntur.

Keywords:

Portal hypertension Cirrhosis, variceshepatic hemodynamics, hepatic venous pressure gradient, liver stiffness, noninvasive methods, ultrasound

DOI

https://doi.org/10.70604/learnint.v1i1.16

References

1. Bosch J, Abraldes JG, Berzigotti A,García-Pagan JC. The clinical use of HPVG measurements in chronic liver disease.. Nat. Rev. Gastroenterol. Hepatol. 6(10), 573–582 (2009).

2. Groszmann RJ, Garcia-Tsao G, Bosch J et al; portal HTN collaborative Group. β-blockers to prevent gastro esophageal varices in patient with cirrhosis, N. Engl. J. Med. 353(21), 2254–2261 (2005).

3. Cheemerla S., Bal Krishnan M. Global Epidemiology of Chronic Liver Disease. Clin. Liver Dis. 2021;17:365–370. Doi: 10.1002/cld.1061. [DOI] [PMC free article] [PubMed] [Google Scholar]

4. Yin X., Guo X., Liu Z., Wang J. Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease. Int. J. Mol. Sci. 2023;24:2844. Doi: 10.3390/ijms24032844. [DOI] [PMC free article] [PubMed] [Google Scholar]

5. Cannito S., Dianzani U., Parola M., Albano E., Sutti S. Inflammatoryprocessesinvolved in NASH-relatedhepatocellular carcinoma. Biosci. Rep. 2023;43:BSR20221271. Doi: 10.1042/BSR20221271. [DOI] [PMC free article] [PubMed] [Google Scholar]

6. Winarto J., Song D.G., Pan C.H. The Role of Fucoxanthin in Non-Alcoholic Fatty Liver Disease. Int. J. Mol. Sci. 2023;24:8203. Doi: 10.3390/ijms24098203. [DOI] [PMC free article] [PubMed] [Google Scholar]

7. Qiao A., Ma W., Jiang Y., Han C., Yan B., Zhou J., Qin G. Hepatic Sam68 Regulates Systemic Glucose Homeostasis and Insulin Sensitivity. Int. J. Mol. Sci. 2022;23:11469. Doi: 10.3390/ijms231911469. [DOI] [PMC free article] [PubMed] [Google Scholar]

8. Qi X., Lai J. Exosomal microRNAs and Progression of Nonalcoholic Steatohepatitis (NASH) Int. J. Mol. Sci. 2022;23:13501. Doi: 10.3390/ijms232113501. [DOI] [PMC free article] [PubMed] [Google Scholar]

9. Eldosoky M.A., Hammad R., Elmadbouly A.A., Aglan R.B., Abdel-Hamid S.G., Alboraie M., Hassan D.A., Shaheen M.A., Rushdi A., Ahmed R.M., et al. Diagnostic Significance of has-miR-21-5p, has-miR-192-5p, has-miR-155-5p, has-miR-199a-5p Panel and Ratios in Hepatocellular Carcinoma on Top of Liver Cirrhosis in HCV-Infected Patients. Int. J. Mol. Sci. 2023;24:3157. Doi: 10.3390/ijms24043157. [DOI] [PMC free article] [PubMed] [Google Scholar]

10. Kunadirek P., Pinjaroen N., Nookaew I., Tangkijvanich P., Chuaypen N. Transcriptomic Analyses Reveal Long Non-Coding RNA in Peripheral Blood Mononuclear Cells as a Novel Biomarker for Diagnosis and Prognosis of Hepatocellular Carcinoma. Int. J. Mol. Sci. 2022;23:7882. Doi: 10.3390/ijms23147882. [DOI] [PMC free article] [PubMed] [Google Scholar]

11. Schelbert S., Schindeldecker M., Drebber U., Witzel H.R., Weinmann A., Dries V., Schirmacher P., Roth W., Straub B.K. Lipid Droplet-Associated Proteins Perilipin 1 and 2: Molecular Markers of Steatosis and MicrovesicularSteatotic Foci in Chronic Hepatitis C. Int. J. Mol. Sci. 2022;23:15456. Doi: 10.3390/ijms232415456. [DOI] [PMC free article] [PubMed] [Google Scholar].

12. Kartasheva-Ebertz D., Gaston J., Lair-Mehiri L., Mottez E., Buivan T.-P., Massault P.-P., Scatton O., Gaujoux S., Vaillant J.-C., Pol S., et al. IL-17A in Human Liver: Significant Source of Inflammation and Trigger of Liver Fibrosis Initiation. Int. J. Mol. Sci. 2022;23:9773. Doi: 10.3390/ijms23179773. [DOI] [PMC free article] [PubMed] [Google Scholar]

13. He L., Chung P.H.Y., Lui V.C.H., Tang C.S.M., Tam P.K.H. Current Understanding in the Clinical Characteristics and Molecular Mechanisms in Different Subtypes of Biliary Atresia. Int. J. Mol. Sci. 2022;23:4841. Doi: 10.3390/ijms23094841. [DOI] [PMC free article] [PubMed] [Google Scholar]

14. Lucas-Ruiz F., Peñín-Franch A., Pons J.A., Ramírez P., Pelegrín P., Cuevas S., Baroja-Mazo A. Emerging Role of NLRP3 Inflammasome and Pyroptosis in Liver Transplantation. Int. J. Mol. Sci. 2022;23:14396. Doi: 10.3390/ijms232214396. [DOI] [PMC free article] [PubMed] [Google Scholar]

15. Sîrbe C., Badii M., Crişan T.O., Bența G., Grama A., Joosten L.A.B., Rednic S., Pop T.L. Detection of Novel Biomarkers in Pediatric Autoimmune Hepatitis by Proteomic Profiling. Int. J. Mol. Sci. 2023;24:7479. Doi: 10.3390/ijms24087479. [DOI] [PMC free article] [PubMed] [Google Scholar]

16. Jastrzębska J., Daniel W.A. Cocaine-Induced Time-Dependent Alterations in Cytochrome P450 and Liver Function. Int. J. Mol. Sci. 2023;24:1632. Doi: 10.3390/ijms24021632. [DOI] [PMC free article] [PubMed] [Google Scholar]

17. Bosch J., Groszmann R.J., Shah V.H. Evolution in the understanding of the pathophysiological basis of portal hypertension: how changes in paradigm are leading to successful new treatments.

18. JHepatol. 2015;62:S121–S130. Doi: 10.1016/j.jhep.2015.01.003. [DOI] [PMC free article] [PubMed] [Google Scholar].

19. Iwakiri Y., Groszmann R.J. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology. 2006;43:S121–S131. Doi: 10.1002/hep.20993. [DOI] [PubMed] [Google Scholar].

20. Hennenberg M., Trebicka J., Sauerbruch T., Heller J. Mechanisms of extrahepatic vasodilation in portal hypertension. Gut. 2008;57:1300–1314. Doi: 10.1136/gut.2007.144584. [DOI] [PubMed] [Google Scholar]

Published

2025-02-21
Statistics
Abstract Display: 54
PDF Downloads: 36

How to Cite

Gorre, V. N., & MD, A. H. (2025). Management and clinical outcomes of chronic liver disease with portal hypertension: a case study. Learnovate-International, 1(1), 8-12. https://doi.org/10.70604/learnint.v1i1.16

Issue

Section

Articles

Deprecated: json_decode(): Passing null to parameter #1 ($json) of type string is deprecated in /home/lapinjournals/domains/lapinjournals.com/public_html/plugins/generic/citations/CitationsPlugin.php on line 68

How to Cite

Gorre, V. N., & MD, A. H. (2025). Management and clinical outcomes of chronic liver disease with portal hypertension: a case study. Learnovate-International, 1(1), 8-12. https://doi.org/10.70604/learnint.v1i1.16